Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02569697 · ClinicalTrials.gov registry record · Phase 1

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

A Phase 1 study of HIV, sponsored by CONRAD.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT02569697: Completed Phase 1 study of HIV, sponsored by CONRAD.

NCT02569697 is a Phase 1 study of HIV that has completed, run by CONRAD. The registered enrollment target is 50 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02569697, a Phase 1 study of HIV, has completed, sponsored by CONRAD.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to develop markers for use of placebo vaginal products and measure markers of mucosal semen exposure among healthy women. The study will also monitor safety of placebo product use.

Conditions Studied

HIV

Interventions

  • OTHER HEC Placebo gel
  • OTHER Placebo Intravaginal Ring
  • OTHER Placebo Vaginal Film
  • OTHER Placebo Vaginal Insert

Study Locations (1)

Virginia

  • Eastern Virginia Medical School - Norfolk

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2015-10
Est. Completion 2016-05
Phase Phase 1
CONRAD

33 total trials

What the finished NCT02569697 record still lists

NCT02569697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 4 interventions - of which HEC Placebo gel is the first listed.

NCT02569697 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT02569697 about?

NCT02569697 is a clinical study titled "Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms". The purpose of this study is to develop markers for use of placebo vaginal products and measure markers of mucosal semen exposure among healthy women. The study will also monitor safety of placebo product use.

What is the current status of trial NCT02569697?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-10. Estimated completion is 2016-05.

What conditions does trial NCT02569697 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT02569697?

The interventions under investigation include: HEC Placebo gel (OTHER), Placebo Intravaginal Ring (OTHER), Placebo Vaginal Film (OTHER), Placebo Vaginal Insert (OTHER).

Who is sponsoring clinical trial NCT02569697?

This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02569697 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02569697's enrollment target sits among peer trials

50 219th of 303 higher than 73 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

  • NCT01746836 · 50 participants · Phase 2

    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02569697, the US trial registry maintained by the National Library of Medicine. NCT02569697 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.